Adm Tronics Unlimited Inc., a Northvale, N.J.-based developer of the Alvio respiratory therapy platform, the Aurex-3 tinnitus treatment modality and the Sonotron musculoskeletal pain therapy system, said it was accepted for membership in the Medical Technology Enterprise Consortium, a biomedical technology consortium collaborating with multiple government agencies to foster integrated research partnerships to speed availability of medical technology solutions to the military, veterans and the civilian population.
Berry Genomics Co. Ltd., of Beijing, and Prenetics Ltd., of Hong Kong, reported they will establish a joint venture that will deliver consumer digital health and genetics testing services in mainland China. The joint venture, which will work on a direct-to-consumer model, will provide an array of integrated digital health and genetics testing services aimed at helping millions of consumers in mainland China understand their genes and how it relates back to their health. The services will launch in the first quarter of next year.
Cochlear Ltd., of Sydney, and Gn Store Nord A/S, of Ballerup, Denmark, signed an agreement to expand their Smart Hearing Alliance collaboration. The Smart Hearing Alliance was established in 2015 to develop hearing solutions. The deepening of this relationship includes joint R&D, shared technology and strengthened global Smart Hearing Alliance commercial collaboration between Cochlear and Gn.
Norcross, Ga.-based Guided Therapeutics Inc., the maker of a testing platform based on its biophotonic technology for the early detection of cervical disease, signed an extension of its distribution agreement with its Russian and Eastern European sales and marketing partner, Newmars Group Kft. The contract extension commits Newmars Group to minimum orders totaling more than $20 million over the next five years, beginning next year in eight Eastern European countries and then in Russia starting in 2020.
Jabil Inc., of St. Petersburg, Fla., reported a collaboration with Recovery Force LLC, of Fishers, Ind., to develop a mobile compression platform to enhance circulation. The platform embeds shape-changing memory fibers into various garments and footwear to produce compressions that the prevent blood clots, reduce post-operative pain, and alleviate joint pain and sore muscles. The technology was developed by Recovery Force and will be manufactured by Jabil.
Horizon Blue Cross Blue Shield of New Jersey, of Newark, N.J., reported it is expanding its laboratory network by adding Quest Diagnostics Inc., of Secaucus, N.J., as an in-network provider of diagnostic information services for its members. Additionally, Bioreference Laboratories Inc., of Elmwood Park, N.J., and Laboratory Corporation of America Holdings, of Burlington, N.C., renewed their status as in-network providers for Horizon Blue Cross Blue Shield of New Jersey.
Itamar Medical Ltd., a Caesarea, Israel-based developer of noninvasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, said the release of the 2019 Fee Schedule from the U.S. Centers for Medicare & Medicaid Services supports broad use of its WatchPAT technology. WatchPAT uses peripheral arterial tone (PAT) technology, providing cardiologists and sleep physicians in the U.S. with accurate sleep diagnosis that enhances clinical decision-making.
Reshape Lifesciences Inc., of San Clemente, Calif., reported the Reshape Balloon system is now available at U.S. Department of Veterans Affairs (VA) medical facilities through the previously reported Reshape Lifesciences partnership with Academy Medical LLC. The Reshape Balloon has been added to Academy Medical's five-year sole source agreement with the VA, which allows any VA surgeon in the U.S. to purchase the Reshape Balloon system from Academy Medical. The FDA-approved Reshape Balloon system involves a nonsurgical weight-loss procedure that uses balloon technology designed to take up room in the stomach to help people lose weight.
Speedx Pty Ltd., of Sydney, Australia, signed agreements with four additional distribution partners in preparation to launch its Resistanceplus GC test in Europe. The new partners are Axonlab (Germany, Benelux and Switzerland), Vircell (Spain), Diamedica (Estonia, Latvia and Lithuania) and Biomedica (Central Eastern Europe). Resistanceplus GC combines Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility.
Visualdx, of Rochester, N.Y., reported an expansion of its partnership with the U.S. Department of Veterans Affairs (VA). The one-year license will give clinical staff in VA's health care facilities access to the Visualdx clinical decision support system software's add-on feature, Dermexpert, to improve diagnostic accuracy in skin-related conditions.